EP2251341A1 — Heterocyclic Janus kinase 3 inhibitors
Assigned to Astellas Pharma Inc · Expires 2010-11-17 · 15y expired
What this patent protects
The invention relates to compound of the formula (I) or its salt, wherein -R 1 , -R 2 , -R 3 , -R 4 , -R 5 , -M-, -X- and -Y= are as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of JAK3 mediated diseases.
USPTO Abstract
The invention relates to compound of the formula (I) or its salt, wherein -R 1 , -R 2 , -R 3 , -R 4 , -R 5 , -M-, -X- and -Y= are as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of JAK3 mediated diseases.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.